EGRP News Flash - January 2, 2013
Funding Opportunity for Utilizing PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detetction Research
The National Cancer Institute (NCI) encourages the submission of grant applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO-screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data.
This Funding Opportunity Announcement, PAR-13-0 36, supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.
Letters of intent are due 30 days prior to application due dates. Applications are due February 20, 2013; June 20, 2013; February 20, 2014; June 20, 2014; February 20, 2015; and June 19, 2015 by 5:00 PM local time of applicant organization.
For cancer epidemiology questions related to biospecimens, contact EGRP's Leah Mechanic, Ph.D., M.P.H., Program Director, Host Susceptibility Factors Branch.
Access the NIH Guide for Grants and Contracts for details:
- PAR-13-036 (U01)